Related Experiment Video
Updated: Jan 16, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.0K
Short- and Long-Term Statin Persistence and Determinants in Patients Initiating Statin Therapy
Mehmet Uzunlulu1, Cundullah Torun1, Erhan Eken1
1Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Department of Internal Medicine, Istanbul, Türkiye.
Medeniyet Medical Journal
|September 29, 2025
Summary
Statin persistence rates are low and declining, especially in younger patients and those on primary prevention. Persistence is higher for patients with existing cardiovascular conditions like hypertension, diabetes, and coronary artery disease.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Statins are crucial for reducing cardiovascular events and mortality.
- Low statin persistence rates are a significant challenge in cardiovascular disease management.
Purpose of the Study:
- To evaluate short- and long-term statin persistence rates.
- To identify factors influencing statin persistence in new users.
Main Methods:
- Retrospective observational study of 903 patients initiating statin therapy (2016-2017).
- Assessed statin persistence in 2018 (short-term) and 2023 (long-term).
- Compared demographic, clinical, and treatment characteristics between persistent and non-persistent groups.
Main Results:
- Short-term persistence (2018) was 55.1%; long-term persistence (2023) was 51.7%.
- Non-persistence was higher in patients under 45 and those on primary prevention (p<0.01).
- Persistence was higher in patients with hypertension, diabetes mellitus, and coronary artery disease (all p<0.01).
Conclusions:
- Statin persistence rates are low and decrease over time.
- Younger patients and those on primary prevention exhibit lower statin persistence.
- Presence of comorbidities like hypertension, diabetes, and CAD is associated with higher statin persistence.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
219
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
219
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
305
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
305
01:05Steady State Concentration
5.8K
A steady state refers to the level of a drug in the body once it has reached an equilibrium between administration and elimination. It represents the point at which the drug administration rate equals the drug elimination rate, resulting in a relatively constant concentration in the body over time. The dynamic equilibrium is crucial to ensure the drug's effectiveness with minimal risk of toxicity.
Most drugs are administered in repeated doses at fixed intervals or through continuous...
Most drugs are administered in repeated doses at fixed intervals or through continuous...
5.8K
01:16Drug Product Stability
226
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
226